These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 20650440)

  • 1. Insurance type influences the use of drug-eluting stents.
    Gaglia MA; Torguson R; Xue Z; Gonzalez MA; Collins SD; Ben-Dor I; Syed AI; Maluenda G; Delhaye C; Hanna N; Wakabayashi K; Kaneshige K; Suddath WO; Kent KM; Satler LF; Pichard AD; Waksman R
    JACC Cardiovasc Interv; 2010 Jul; 3(7):773-9. PubMed ID: 20650440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selection of patients for drug-eluting stents based on insurance coverage: pay or don't play.
    Krone RJ
    JACC Cardiovasc Interv; 2010 Jul; 3(7):780-2. PubMed ID: 20650441
    [No Abstract]   [Full Text] [Related]  

  • 3. African-American patients are less likely to receive drug-eluting stents during percutaneous coronary intervention.
    Gaglia MA; Shavelle DM; Tun H; Bhatt J; Mehra A; Matthews RV; Clavijo L
    Cardiovasc Revasc Med; 2014 Jun; 15(4):214-8. PubMed ID: 24814420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disparity in drug-eluting stent utilization by insurance type.
    Kao J; Vicuna R; House JA; Rumsfeld JS; Ting HH; Spertus JA
    Am Heart J; 2008 Dec; 156(6):1133-40. PubMed ID: 19033009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of insurance type on adverse cardiac events after percutaneous coronary intervention.
    Gaglia MA; Torguson R; Xue Z; Gonzalez MA; Ben-Dor I; Maluenda G; Mahmoudi M; Sardi G; Wakabayashi K; Kaneshige K; Suddath WO; Kent KM; Satler LF; Pichard AD; Waksman R
    Am J Cardiol; 2011 Mar; 107(5):675-80. PubMed ID: 21184997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insurance status and outcome after intracerebral hemorrhage: findings from Get With The Guidelines-stroke.
    James ML; Grau-Sepulveda MV; Olson DM; Smith EE; Hernandez AF; Peterson ED; Schwamm LH; Bhatt DL; Fonarow GC
    J Stroke Cerebrovasc Dis; 2014 Feb; 23(2):283-92. PubMed ID: 23537567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug-eluting stents and the use of percutaneous coronary intervention among patients with class I indications for coronary artery bypass surgery undergoing index revascularization: analysis from the NCDR (National Cardiovascular Data Registry).
    Frutkin AD; Lindsey JB; Mehta SK; House JA; Spertus JA; Cohen DJ; Rumsfeld JS; Marso SP;
    JACC Cardiovasc Interv; 2009 Jul; 2(7):614-21. PubMed ID: 19628183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term clinical and economic analysis of the Endeavor drug-eluting stent versus the Driver bare-metal stent: 4-year results from the ENDEAVOR II trial (Randomized Controlled Trial to Evaluate the Safety and Efficacy of the Medtronic AVE ABT-578 Eluting Driver Coronary Stent in De Novo Native Coronary Artery Lesions).
    Eisenstein EL; Wijns W; Fajadet J; Mauri L; Edwards R; Cowper PA; Kong DF; Anstrom KJ
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1178-87. PubMed ID: 20129543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolonged clopidogrel use after bare metal and drug-eluting stent placement: the Veterans Administration drug-eluting stent study.
    Faxon DP; Lawler E; Young M; Gaziano M; Kinlay S
    Circ Cardiovasc Interv; 2012 Jun; 5(3):372-80. PubMed ID: 22668555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trends in immediate breast reconstruction across insurance groups after enactment of breast cancer legislation.
    Yang RL; Newman AS; Lin IC; Reinke CE; Karakousis GC; Czerniecki BJ; Wu LC; Kelz RR
    Cancer; 2013 Jul; 119(13):2462-8. PubMed ID: 23585144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of sex on 3-year outcome after percutaneous coronary intervention using bare-metal and drug-eluting stents in previously untreated coronary artery disease: insights from the RESEARCH (Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated at Rotterdam Cardiology Hospital) Registries.
    Onuma Y; Kukreja N; Daemen J; Garcia-Garcia HM; Gonzalo N; Cheng JM; van Twisk PH; van Domburg R; Serruys PW;
    JACC Cardiovasc Interv; 2009 Jul; 2(7):603-10. PubMed ID: 19628181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences in utilization of drug-eluting stents by race and payer.
    Hannan EL; Racz M; Walford G; Clark LT; Holmes DR; King SB; Sharma S
    Am J Cardiol; 2007 Oct; 100(8):1192-8. PubMed ID: 17920356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The costs of drug-eluting coronary stents among Medicare beneficiaries.
    Groeneveld PW; Matta MA; Greenhut AP; Yang F
    Am Heart J; 2008 Jun; 155(6):1097-105. PubMed ID: 18513525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term clinical and economic analysis of the Endeavor zotarolimus-eluting stent versus the cypher sirolimus-eluting stent: 3-year results from the ENDEAVOR III trial (Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).
    Eisenstein EL; Leon MB; Kandzari DE; Mauri L; Edwards R; Kong DF; Cowper PA; Anstrom KJ;
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1199-207. PubMed ID: 20129546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative effectiveness of drug-eluting versus bare-metal stents in elderly patients undergoing revascularization of chronic total coronary occlusions: results from the National Cardiovascular Data Registry, 2005-2008.
    Patel MR; Marso SP; Dai D; Anstrom KJ; Shunk KA; Curtus JP; Brennan JM; Sedrakyan A; Messenger JC; Douglas PS
    JACC Cardiovasc Interv; 2012 Oct; 5(10):1054-61. PubMed ID: 23078736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and effectiveness of drug-eluting stents versus bare-metal stents in elderly patients with small coronary vessel disease.
    Puymirat E; Mangiacapra F; Peace A; Ntarladimas Y; Conte M; Bartunek J; Vanderheyden M; Wijns W; de Bruyne B; Barbato E
    Arch Cardiovasc Dis; 2013 Nov; 106(11):554-61. PubMed ID: 24231052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stent thrombosis, clinical events, and influence of prolonged clopidogrel use after placement of drug-eluting stent data from an observational cohort study of drug-eluting versus bare-metal stents.
    Park DW; Yun SC; Lee SW; Kim YH; Lee CW; Hong MK; Cheong SS; Kim JJ; Park SW; Park SJ
    JACC Cardiovasc Interv; 2008 Oct; 1(5):494-503. PubMed ID: 19463351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of race and ethnicity on outcomes with drug-eluting and bare metal stents: results in 423 965 patients in the linked National Cardiovascular Data Registry and centers for Medicare & Medicaid services payer databases.
    Kumar RS; Douglas PS; Peterson ED; Anstrom KJ; Dai D; Brennan JM; Hui PY; Booth ME; Messenger JC; Shaw RE
    Circulation; 2013 Apr; 127(13):1395-403. PubMed ID: 23547179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug-eluting versus bare-metal stents in the treatment of patients with ST-segment elevation myocardial infarction.
    Hannan EL; Racz M; Walford G; Holmes DR; Jones RH; Sharma S; Katz S; King SB
    JACC Cardiovasc Interv; 2008 Apr; 1(2):129-35. PubMed ID: 19463290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 3-year clinical outcome of patients with chronic total occlusion treated with drug-eluting stents.
    De Felice F; Fiorilli R; Parma A; Nazzaro M; Musto C; Sbraga F; Caferri G; Violini R
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1260-5. PubMed ID: 20129553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.